Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 23;8:11033. doi: 10.1038/s41598-018-29349-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Enhanced SSTR-2 expression by COX-2 overexpression and the TAA treatment. (A) Relative level of SSTR-2 expression in L02 cells transfected with the COX-2 overexpression plasmid following the addition of celecoxib at a final concentration of 20 or 40 μM (Western blot). Control group: L02 cells transfected with the empty pcDNA3.1 plasmid; COX-2 group: L02 cells transfected with the COX-2 overexpression plasmid; COX-2+ celecoxib20 group: L02 cells transfected with the COX-2 overexpression plasmid and treated with 20 μM celecoxib; COX-2+ celecoxib40 group: L02 cells transfected with the COX-2 overexpression plasmid and treated with 40 μM celecoxib. ^**P < 0.01 compared with the control group, ^#P < 0.01 compared with the COX-2 group. (B) Western blots showing SSTR-2 and COX-2 levels in each group. The group of blots was cropped from different gels. (C) Western blot analysis of cells treated with final concentrations of 20, 40, or 80 mg/L TAA or the combination of 80 mg/L TAA and celecoxib at final concentrations of 20 or 40 μM. Control: L02 cells treated with vehicle; TAA20, TAA40 and TAA80: L02 cells treated with 20, 40, and 80 mg/L TAA, respectively; TAA80+ celecoxib20: L02 cells treated with TAA (80 mg/L) plus celecoxib (20 μM); TAA80+ celecoxib40: L02 cells treated with TAA (80 mg/L) plus celecoxib (40 μM). ^*P < 0.05 compared with the control group. ^**P < 0.01 compared with the control group; ^#P < 0.01 compared with the TAA80 group. (D) Western blots showing SSTR-2 and COX-2 levels in each group. n = 3 samples per group. The group of blots was cropped from different gels.